Cargando…

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

Detalles Bibliográficos
Autores principales:	Sznol, Mario, Fishman, Mayer, Escudier, Bernard, McDermott, David F, Kluger, Harriet, Stadler, Walter M, Perez-Gracia, Jose, McNeel, Douglas G, Curti, Brendan D, Harrison, Michael R, Plimack, Elizabeth R, Appleman, Leonard, Fong, Lawrence, Drake, Charles G, Young, Tina C, Chasalow, Scott D, Ross-MacDonald, Petra, Simon, Jason S, Walker, Dana, Choueiri, Toni K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649555/ http://dx.doi.org/10.1186/2051-1426-3-S2-P197

Ejemplares similares

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
por: Weber, Jeffrey, et al.
Publicado: (2015)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
por: Motzer, Robert J, et al.
Publicado: (2021)

Circulating KIM-1 is a minimally invasive biomarker correlated with treatment response to nivolumab in patients with metastatic renal cell carcinoma
por: Xu, Wenxin, et al.
Publicado: (2023)

TCR diversity – a universal cancer immunotherapy biomarker?
por: McNeel, Douglas G.
Publicado: (2016)

Toward a More Conclusive Understanding of the Relationship between Musical Training and Reading
por: Jantzen, McNeel G.
Publicado: (2017)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
por: Atkins, Michael B., et al.
Publicado: (2022)

Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination
por: Becker, Jordan T, et al.
Publicado: (2013)

Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression
por: Jeon, Donghwan, et al.
Publicado: (2022)

B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA
por: Rastogi, Ichwaku, et al.
Publicado: (2023)

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
por: Atkins, Michael B, et al.
Publicado: (2023)

The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor Therapy
por: Smith, Heath A., et al.
Publicado: (2010)

Sipuleucel-T: immunotherapy for advanced prostate cancer
por: Olson, Brian M, et al.
Publicado: (2011)

B lymphocyte mediated antigen presentation of plasmid DNA
por: Colluru, Viswa Teja, et al.
Publicado: (2013)

Monitoring Regulatory Immune Responses in Tumor Immunotherapy Clinical Trials
por: Olson, Brian M., et al.
Publicado: (2013)

SSX expression and function in prostate cancer
por: Bloom, Jordan E, et al.
Publicado: (2013)

SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer
por: Bloom, Jordan E., et al.
Publicado: (2016)

B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines
por: Colluru, Viswa Teja, et al.
Publicado: (2016)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Vaccines as treatments for prostate cancer
por: Rastogi, Ichwaku, et al.
Publicado: (2023)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Epitope optimization of a DNA vaccine targeting SSX-2 leads to PD-1 upregulation on antigen-specific CD8 T cells and PD-L1 upregulation on tumor cells
por: Rekoske, Brian, et al.
Publicado: (2013)

Editorial: Overlap of Neural Systems for Processing Language and Music
por: Jantzen, McNeel G., et al.
Publicado: (2016)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
por: Aziz, Saadia A, et al.
Publicado: (2013)

Heterogeneity in past-year smoking, current tobacco use, and smoking cessation behaviors among light and/or non-daily smokers
por: Omole, Toluwa, et al.
Publicado: (2020)

Prevalence of current large cigar versus little cigar/cigarillo smoking among U.S. adults, 2018–2019
por: Phan, Lilianna, et al.
Publicado: (2021)

Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response
por: Johnson, Laura E., et al.
Publicado: (2012)

Neurophysiological evidence that musical training influences the recruitment of right hemispheric homologues for speech perception
por: Jantzen, McNeel G., et al.
Publicado: (2014)

Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination
por: Johnson, Laura E., et al.
Publicado: (2017)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
por: Regan, Meredith M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_smkl6qild6vs5tn83nesn6a19s